Resolvin D1-based nanodrugs have no toxic effects, can be stored for a long time, and appear to be more effective in reducing the extent of inflammation and bacterial colonization in the lungs of mice and in cells obtained from volunteers with cystic fibrosis.
When nanoparticles were administered for 1 week to mice, no signs of side effects were observed. Resolvin D1-containing nanoparticles maintain efficacy even when stored for several days at 4 °C.
When administered to mice with lung mucus accumulation, chronic inflammation, and respiratory infections as occurs in patients with cystic fibrosis, resolvin D1-containing nanodrugs reduced the number of inflammatory cells and bacteria present in the lungs. Treatment of white blood cells obtained from volunteers with cystic fibrosis with resolvin D1 nanoformulations increased their ability to clear bacterial infection.

These results demonstrate the ability of these nanodrugs to activate the resolution of inflammation that is ineffective in patients with cystic fibrosis and paves the road for a new strategy to alleviate lung disease that plagues and impacts the lives of persons with cystic fibrosis.